Acrivon Therapeutics, Inc. (ACRV): R&D Expense
$59.99M
Year ended 2025-12-31
$57.40M
Trailing 12 months to 2026-06-30
+35.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.99M | -6.3% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $63.99M | +39.0% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $46.02M | +92.2% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $23.95M | n/a | 2024-03-28, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $59.99M | -6.3% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $9.16M | -23.1% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $67.75M | -0.2% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $49.06M | -24.1% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $5.74M | -27.9% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $23.52M | -75.4% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $9.90M | -23.8% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
Compare ACRV, CTXR, SLN, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗